×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EOLS – evolus, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EOLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/13
09:02 am
eols
Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.
1/9
07:03 pm
eols
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]
Low
Report
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]
1/9
12:46 pm
eols
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
1/9
09:01 am
eols
Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]
Low
Report
Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]
1/9
08:30 am
eols
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Medium
Report
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
12/24
08:02 am
eols
Evolus (NASDAQ:EOLS) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Medium
Report
Evolus (NASDAQ:EOLS) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/19
07:08 pm
eols
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]
Low
Report
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]
12/1
09:02 pm
eols
Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.
Medium
Report
Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
08:35 am
eols
Form 8-K Evolus, Inc. For: Jan 09
Low
Report
Form 8-K Evolus, Inc. For: Jan 09
12/29
06:42 pm
eols
Form 4 Evolus, Inc. For: Dec 22 Filed by: MOATAZEDI DAVID
Low
Report
Form 4 Evolus, Inc. For: Dec 22 Filed by: MOATAZEDI DAVID
12/29
06:42 pm
eols
Form 4 Evolus, Inc. For: Dec 22 Filed by: Avelar Rui
Low
Report
Form 4 Evolus, Inc. For: Dec 22 Filed by: Avelar Rui
11/14
04:51 pm
eols
Form SCHEDULE 13G/A Evolus, Inc. Filed by: Nantahala Capital Management, LLC
Low
Report
Form SCHEDULE 13G/A Evolus, Inc. Filed by: Nantahala Capital Management, LLC
11/14
02:30 pm
eols
Form SCHEDULE 13G/A Evolus, Inc. Filed by: Caligan Partners LP
Low
Report
Form SCHEDULE 13G/A Evolus, Inc. Filed by: Caligan Partners LP
11/14
01:37 pm
eols
Form SCHEDULE 13G/A Evolus, Inc. Filed by: LYNCH TIMOTHY P
Low
Report
Form SCHEDULE 13G/A Evolus, Inc. Filed by: LYNCH TIMOTHY P
11/5
05:03 pm
eols
Form 10-Q Evolus, Inc. For: Sep 30
Medium
Report
Form 10-Q Evolus, Inc. For: Sep 30
11/5
04:13 pm
eols
Form 8-K Evolus, Inc. For: Nov 05
Medium
Report
Form 8-K Evolus, Inc. For: Nov 05
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/4
Form 4/A Evolus, Inc. For: Jun 03 Filed by: Alphaeon Corp
16.7%
11/7 Evolus Announces Pricing of Public Offering of Common Stock 14.3%
7/17 Form 4 Evolus, Inc. For: Jul 15 Filed by: Parschauer Karah Herdman 11.6%
5/17 Form 424B4 Evolus, Inc. 8.0%
8/8 Juvly Aesthetics Continues Its Leadership Expansion with Appointment of a Chief People Officer 6.7%
2/25 Form 10-K Evolus, Inc. For: Dec 31 6.0%
5/21 ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt 5.4%
7/16 Form 8-K Evolus, Inc. For: Jul 15 4.8%
10/15 Evolus Inc (NASDAQ: EOLS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.4%
5/31 Form 4 Evolus, Inc. For: May 31 Filed by: SILVERNAIL LAUREN P 4.2%
11/7 Evolus Announces Pricing of Public Offering of Common Stock 14.3%
7/17 Form 4 Evolus, Inc. For: Jul 15 Filed by: Parschauer Karah Herdman 11.6%
5/17 Form 424B4 Evolus, Inc. 8.0%
8/8 Juvly Aesthetics Continues Its Leadership Expansion with Appointment of a Chief People Officer 6.7%
2/25 Form 10-K Evolus, Inc. For: Dec 31 6.0%
5/21 ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt 5.4%
7/16 Form 8-K Evolus, Inc. For: Jul 15 4.8%
10/15 Evolus Inc (NASDAQ: EOLS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.4%
5/31 Form 4 Evolus, Inc. For: May 31 Filed by: SILVERNAIL LAUREN P 4.2%
TOP News Decliners
5/15
ALPHAEON Corporation sells 4 million shares in Evolus Inc.
-11.2%
8/13 Evolus Inc (NASDAQ: EOLS) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock. -11.0%
3/17 Form DEF 14A Evolus, Inc. For: May 01 -10.7%
2/25 Q4/2019 12/31/2019 EPS -0.470 ZacksConsensus -0.850 ActVsEst 0.380 - Beat -8.6%
3/27 Evolus Inc (NASDAQ: EOLS) had its price target lowered by analysts at HC Wainwright from $31.00 to $16.00. They now have a "buy" rating on the stock. -8.0%
3/4 Evolus Provides Update on International Trade Commission (ITC) Case -7.7%
1/9 Form 8-K Evolus, Inc. For: Jan 09 -7.0%
1/10 Form 8-K Evolus, Inc. For: Jan 10 -6.8%
3/3 Evolus to Participate in Barclays 2020 Global Healthcare Conference -6.3%
8/12 Q2/2019 6/30/2019 EPS -1.370 ZacksConsensus -0.960 ActVsEst (0.410) - Miss -6.2%
8/13 Evolus Inc (NASDAQ: EOLS) had its "outperform" rating re-affirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock. -11.0%
3/17 Form DEF 14A Evolus, Inc. For: May 01 -10.7%
2/25 Q4/2019 12/31/2019 EPS -0.470 ZacksConsensus -0.850 ActVsEst 0.380 - Beat -8.6%
3/27 Evolus Inc (NASDAQ: EOLS) had its price target lowered by analysts at HC Wainwright from $31.00 to $16.00. They now have a "buy" rating on the stock. -8.0%
3/4 Evolus Provides Update on International Trade Commission (ITC) Case -7.7%
1/9 Form 8-K Evolus, Inc. For: Jan 09 -7.0%
1/10 Form 8-K Evolus, Inc. For: Jan 10 -6.8%
3/3 Evolus to Participate in Barclays 2020 Global Healthcare Conference -6.3%
8/12 Q2/2019 6/30/2019 EPS -1.370 ZacksConsensus -0.960 ActVsEst (0.410) - Miss -6.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: